ClinicalTrials.gg
RecruitingNCT07220265Updated Oct 22, 2026

Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers

An interventional study of Phenylalanine (Phe) and Placebo in Carrier of Phenylketonuria and Healthy, sponsored by University of Missouri-Columbia. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University of Missouri-Columbia · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 93 studies in Phenylketonurias with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Phenylketonurias · United States.

Planned enrollment
29th of 63
36 · median 33
Started
2025
with 5 others
No phase
14 of 93
3 open now
Primary completion
2027-03
later than 6 of 20 live
Registered
88th of 93
by date
Lead sponsor
5 of 93
University of Missouri-Columbia

Among the 93 studies in Phenylketonurias with a site in United States, this one is the 29th largest by planned enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2025, is one of 14 with no phase, reaches primary completion later than 6 of the 20 other live ones, and was the 88th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

16 of the 93 studies in Phenylketonurias with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Phenylketonurias with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to advance our understanding of the cognitive and neurophysiologic sequelae associated with suboptimal phenylalanine (Phe) metabolism in heterozygous carriers of phenylketonuria (PKU). The main questions it aims to answer are:

  • Do PKU carriers experience prolonged elevations in brain Phe levels following oral ingestion of dietary Phe?
  • Do PKU carriers experience disruptions in cognitive functioning following oral ingestion of dietary Phe?
  • Do PKU carriers experience atypical brain activity following oral ingestion of dietary Phe? Researchers will compare PKU carriers and non-carriers following oral ingestion of dietary Phe and a placebo.

Participants will:

  • Consume Phe or a placebo at two separate visits to our facility
  • At each visit, they will complete a series of MRIs and cognitive tests throughout the day
Read the detailed description

Limitations inherent in past studies of phenylketonuria (PKU) carriers (e.g., poor genetic characterization of sample resulting in inclusion of homozygous non-PKU relatives, reliance on rudimentary or overly broad behavioral assessment tools) make it difficult to conclude the extent to which neurophysiologic and cognitive processes are affected in these individuals. To address this gap in the literature, we propose to conduct a double-blind crossover study in a sample of genetically-confirmed sample of 18 heterozygous PKU carriers and 18 non-carriers. A principled investigation of the effects of elevated phenylalanine (Phe) on neurocognition will involve participants performing an fMRI n-back WM task, resting state scan, and a battery of select cognitive tests at 3 timepoints: baseline (pre-load), 2 hours and 4 hours after starting oral administration of Phe or placebo. Blood and brain levels of Phe and Tyr will also be assessed at each timepoint.

03

Conditions studied

  • Carrier of Phenylketonuria
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-60 years
  • For the PKU carrier group: Individuals who are the parent of an individual with PKU or who are otherwise have confirmed PKU carrier status (e.g., a sibling of someone with PKU who has had genetic testing done)
  • For the non-carrier group: Individuals who do not have PKU or a family history of PKU

Exclusion criteria

Exclusion Criteria:

  • Obesity as defined by a (BMI) over 30*
  • Taking oral on the day of testing session*
  • Positive cotinine urine test showing nicotine use
  • History of major neurologic condition (e.g., multiple sclerosis, severe closed head injury, Parkinson's disease)) unrelated to PKU and known to adversely impact brain health and function
  • for safe MRI participation such as (a) pregnancy or plans to become pregnant during period of study enrollment; or (b) metallic objects inside the body (e.g., surgical staples left in the body following surgery, middle ear prosthesis, metal foreign objects lodged inside the eye, heart pacemakers).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Other
    PKU Carriers

    Heterozygous carriers of a pathogenic variant of the PAH gene associated with phenylketonuria (PKU)

    Dietary Supplement: Phenylalanine (Phe) · Dietary Supplement: Placebo

  • Other
    Non-Carriers

    Individuals who do not carry a pathogenic variant of the PAH gene

    Dietary Supplement: Phenylalanine (Phe) · Dietary Supplement: Placebo

Interventions

  • Dietary supplementPhenylalanineStudies of PhenylalaninePhenylalanine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral ingestion of phenylalanine (Phe)

  • Dietary supplementPlacebo

    Oral ingestion of Placebo (Vitamin C)

06

What researchers measure

Primary outcomes

  1. Blood Phenylalanine Levels

    Time frame: 3 timepoints: baseline (pre-load), 2 hours and 4 hours after starting oral administration of Phe or placebo

  2. Brain Phenylalanine Levels

    Brain Phenylalanine Levels estimated using magnetic resonance spectroscopy (MRS)

    Time frame: 3 timepoints: baseline (pre-load), 2 hours and 4 hours after starting oral administration of Phe or placebo

  3. Brain Phenylalanine-to-Tyrosine Ratio

    Ratio of Phenylalanine-to-Tyrosine concentrations in the brain as estimated using magnetic resonance spectroscopy (MRS)

    Time frame: 3 timepoints: baseline (pre-load), 2 hours and 4 hours after starting oral administration of Phe or placebo

  4. Neural Activity during Go/No-Go Task

    Pattern of brain activation as captured using functional MRI while performing a go/no-go inhibitory task

    Time frame: 3 timepoints: baseline (pre-load), 2 hours and 4 hours after starting oral administration of Phe or placebo

  5. Operational Span Task

    Performance-based measure of working memory ability. In this task, participants first solve a math problem and then see a letter, and then solve another math problem, and see another letter. This math-letter sequence is repeated from three to seven times for each trial with an unpredictable length each time. After each math-letter sequence, participants are asked to recall, in order, the preceding letters. Scores are calculated by summing the number of letters correctly recalled in the correct order.

    Time frame: 3 timepoints: baseline (pre-load), 2 hours and 4 hours after starting oral administration of Phe or placebo

  6. Multi-Source Interference Task

    Performance-based measure of focused attention. ). In this task, participants are shown a display containing three horizontally-aligned numbers (i.e., 1, 2, or 3) and asked to respond as quickly as possible to the location (position #1, 2, or 3) of the number stimulus that is different from the others. The location may be congruent (e.g., "323") or incongruent (e.g., "112") with identity of the target number. Mean response time and error rate will served as the outcome variables.

    Time frame: 3 timepoints: baseline (pre-load), 2 hours and 4 hours after starting oral administration of Phe or placebo

  7. Grooved Pegboard Test

    Performance-based measure of processing speed \& fine motor control

    Time frame: 3 timepoints: baseline (pre-load), 2 hours and 4 hours after starting oral administration of Phe or placebo

  8. Resting-State Functional Connectivity

    Synchronization of neural activity within brain networks as measured by functional MRI while participants are at rest

    Time frame: 3 timepoints: baseline (pre-load), 2 hours and 4 hours after starting oral administration of Phe or placebo

Secondary outcomes

  1. Brain concentrations of glutamate, glutathione, creatine, and other metabolites

    Concentrations of various brain metabolites as estimated using magnetic resonance spectroscopy (MRS)

    Time frame: 3 timepoints: baseline (pre-load), 2 hours and 4 hours after starting oral administration of Phe or placebo

  2. PROMIS Anxiety - Short Form 8a

    A patient-reported outcome (PRO) measure assessing symptoms of anxiety. Scores range from 8 to 40, with higher scores indicating more/worse symptoms.

    Time frame: Baseline only

  3. PROMIS Depression - Short Form 8a

    A patient-reported outcome (PRO) measure assessing symptoms of depression. Scores range from 8 to 40, with higher scores indicating more/worse symptoms.

    Time frame: Baseline only

  4. PROMIS Sleep - Short Form 8a

    A patient-reported outcome (PRO) measure assessing symptoms of sleep disturbance. Scores range from 8 to 40, with higher scores indicating more/worse symptoms.

    Time frame: Baseline only

  5. PROMIS Fatigue - Short Form 8a

    A patient-reported outcome (PRO) measure assessing symptoms of fatigue. Scores range from 8 to 40, with higher scores indicating more/worse symptoms.

    Time frame: Baseline only

  6. PROMIS Cognitive Function - Short Form 8a

    A patient-reported outcome (PRO) measure assessing symptoms of cognitive dysfunction. Scores range from 8 to 40, with higher scores indicating more/worse symptoms.

    Time frame: Baseline only

  7. • Executive Function, Attention, and Speed Symptom Inventory (EASSI)

    Patient-reported outcome (PRO) measure of everyday symptoms of cognitive dysfunction. Scores range from 72 to 360, with higher scores indicating more/worse symptoms.

    Time frame: Baseline only

  8. Adult ADHD Self-Report Scale (ASRS)

    Patient-reported outcome (PRO) measure of ADHD symptoms. Scores range from 0 to 124, with higher scores indicating more/worse symptoms.

    Time frame: Baseline only

  9. Matrix Reasoning subtest from the WASI-2

    Performance-based measure of fluid intelligence

    Time frame: Baseline only

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Demographic, blood amino acid levels, cognitive test performance, and MRI data (structural, spectroscopy, functional) will be acquired from 18 healthy adult carriers for PKU and 18 matched healthy controls. All data will be de-identified prior to deposit in the NIMH Data Archive (NDA).

Supporting information: Study protocol, Analytic code

Time frame: Data will be made available when the award ends (currently 04/30/2027)or when a publication is available, whichever comes first. As required by NDA, studies will also be created that contain the data used for every publication. Those studies will be shared when the pre-print is available. NDA will make decisions about how long to preserve the data, but that data archive has not deleted any deposited data up to now.

Access criteria: All data will be deposited to the NDA. To request access of the data, researchers will use the standard processes at NDA, and the NDA Data Access Committee will decide which requests to grant. The standard NDA data access process allows access for one year and is renewable.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.

Of 33 interventional studies with no phase under Phenylketonurias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 28. This study's planned 14 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2026 → Mar 2027 and completion Dec 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2025
First posted
Oct 23, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Mar 1, 2027was Dec 2026
CompletionEst.
Mar 1, 2027was Dec 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Mar 1, 2027
Oct 22, 2026
Study completion
Dec 31, 2026→Mar 1, 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Dec 31, 2026→Mar 1, 2027
    Study completion Dec 31, 2026→Mar 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07220265
Responsible party
Shawn Christ (Professor, Psychological Sciences, University of Missouri-Columbia) — Principal investigator
First posted
Oct 23, 2025
Start date
Dec 19, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Shawn Christ
Contact
christse@missouri.edu
573-884-8140

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phenylalanine

Start the discussion